Dr. Reddy's Wins CDSCO Nod for Generic Oral Semaglutide Amid Legal and Competitive Headwinds

Dr. Reddy's Laboratories has secured CDSCO approval for its generic oral semaglutide tablets (3 mg, 7 mg, 14 mg) in India, entering the fast-growing ₹1,600 crore GLP-1 market for diabetes and weight management. The generic demonstrated non-inferiority to Novo Nordisk's Rybelsus in clinical studies. The approval follows the expiry of Novo Nordisk's core semaglutide patent in March 2026, triggering a wave of domestic launches from Sun Pharma, Zydus, Torrent, Lupin, and others. Dr. Reddy's targets ~7% market share, aiming to replicate Torrent's early traction. However, significant challenges remain: Patent Litigation: Novo Nordisk holds an oral formulation patent (via SNAC technology) valid until 2031 and is suing Indian firms over alleged infringement. The dispute centres on SNAC concentration — Novo claims 0.65–2.1 mmol, while competitors like Torrent use lower levels (0.53 mmol). Pricing Pressure: With 40+ generics expected, prices could fall 50–85%, compressing margins across the segment. Regulatory Setback: Brazil's ANVISA recently rejected Dr. Reddy's semaglutide filing (Embeltah) over efficacy and quality concerns, limiting near-term international expansion. Analyst views are divided: HSBC upgraded to 'Buy' (target ₹1,445) citing long-term GLP-1 potential, while Citi retains 'Sell' (target ₹1,070) flagging legal risks and commoditisation. For Dr. Reddy's, the India approval is a strategic win, but sustained success hinges on navigating patent litigation, executing a competitive pricing strategy, and differentiating in an increasingly crowded market.